XML 59 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Product sales, net $ 8,629,928 $ 9,827,444
Cost of products sold 2,195,340 3,034,832
Gross profit 6,434,588 6,792,612
Selling, general and administrative expenses 12,295,330 13,135,796
Research and development expenses 858,767 701,378
Depreciation and amortization expense 37,448 61,912
Total operating expenses 13,191,545 13,899,086
Loss from operations (6,756,957) (7,106,474)
Interest income 60,265 125,527
Gain on sale of net operating losses 1,983,095 0
Loss before provision for income taxes (4,713,597) (6,980,947)
Net loss (4,713,597) (6,980,947)
Net loss attributable to noncontrolling interests 0 (51,843)
Net loss attributable to Milestone Scientific Inc. $ (4,713,597) $ (6,929,104)
Net loss per share applicable to common stockholders—    
Basic and Diluted (in dollars per share) $ (0.06) $ (0.1)
Weighted average shares outstanding and to be issued—    
Basic and diluted (in shares) 79,791,188 72,775,781